|
(Health-NewsWire.Net, December 01, 2020 ) The study involved two major activities in estimating the current market size of the human microbiome market. Exhaustive research was conducted to collect information on the market as well as its peer and parent markets.
The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
Expected Revenue Growth
The human microbiome market is expected to grow from USD 942 million in 2024 to USD 1,731 million by 2027, at a CAGR of 22.5% during 2024–2027.
Global Growth Boosters:
The human microbiome field is a rapidly emerging area of biology and offers new routes for personalized healthcare strategies, improved nutrition, animal welfare, and industrial products. Owing to this, the applications of microbiome research are growing at a significant rate.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904
Global Leaders:
The major players in the human microbiome market include Enterome Bioscience (France), E.I. du Pont de Nemours and Company (DuPont) (US), 4D Pharma (UK), and Seres Therapeutics (US). Various growth strategies have been adopted by these players, such as product launches, agreements, and acquisitions to increase their presence in the global human microbiome market.
Enterome Bioscience (France) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat microbiome-associated diseases with a focus on IBDs, Crohn’s, and cancer (glioblastoma, colon, pancreatic, lung, and breast) indications. In 2018, the company raised USD 38.5 million (EUR 32 million) in a Series D financing, which will be used for clinical trials of Enterome’s lead development programs, namely, Phase 2 study of the company’s oral FimH blocker EB8018 for the treatment of Crohn’s disease and Phase 1b study of EO2315, a novel immuno-oncology candidate, in patients with aggressive brain cancer (glioblastoma multiforme).
Moreover, the company received a loan facility of USD 44.3 million (EUR 40 million) from the European Investment Bank (EIB) to support the acceleration of its pipeline and technology development. Such financing will help the company to conduct research on its microbiome-based products.
Seres Therapeutics (US) is one of the emerging players operating in this market. Its is engaged in developing a range of novel therapeutic products based on the human microbiome. The company’s microbiome therapeutics platform allows to significantly reduce the time typically required to advance therapeutics to the clinic, and ultimately, to the market. The company focuses on R&D to launch advanced products in the market. In 2017, the company invested 278% of its total revenue in R&D activities.
Europe to account for the largest share of the human microbiome market in 2022
On the basis of region, the global human microbiome market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). Europe is expected to account for the largest share of the global human microbiome market in 2022. The large share of this regional segment is mainly due to the high research activity in this region.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
|
